BackNeuphoria Therapeutics Overview

Neuphoria Therapeutics Receivables

Latest receivables for NEUP: $810K.

Get informed when a big investor buys or sells

+ Follow
Receivables
$813431.00
↓ 93.19% YoYΔ $-11.13M vs prior year quarter

Peer trimmed avg / median

Loading

Neuphoria Therapeutics Receivables History

Loading

Neuphoria Therapeutics vs. peers: Receivables Comparison

Loading

Neuphoria Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Neuphoria Therapeutics (NEUP) FAQ

As of the most recent data (June 2026), NEUP shows a receivables of $810K. That compares with $12M in the prior-year period — down 93.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NEUP's receivables is now $810K (was $12M) — a 93.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Neuphoria Therapeutics is outperforming or lagging.

Tracking NEUP's receivables over time shows whether Neuphoria Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $810K That compares with $12M in the prior-year period — down 93.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Neuphoria Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $810K) with ownership activity and broader fundamentals.

Neuphoria Therapeutics's receivables is $810K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.